Improvement of chronic allograft nephropathy by reduction of calcineurin inhibitor and introduction of mycophenolic acid

被引：0
|
作者：
Merkel, Saskia [1 ]
Mengel, Michael [2 ]
Haller, Hermann [1 ]
Schwarz, Anke [1 ]
机构：
[1] Sch Med, Dept Nephrol, Hannover, Germany
[2] Sch Med, Dept Pathol, Hannover, Germany
来源：
TRANSPLANT INTERNATIONAL | 2007年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：238 / 238
页数：1
相关论文
共 50 条
  • [1] Improvement of renal transplant function by reduction of calcineurin inhibitor and introduction of mycophenolate mofetil acid in patients with chronic allograft nephropathy.
    Merkel, Saskia
    Mengel, Michael
    Haller, Hermann
    Schwarz, Anke
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 533 - 533
  • [2] Calcineurin inhibitor nephrotoxicity: reduction in dose results in marked improvement in renal function in patients with coexisting chronic allograft nephropathy
    Pilmore, HL
    Dittmer, ID
    CLINICAL TRANSPLANTATION, 2002, 16 (03) : 191 - 195
  • [3] Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy
    Falger, Jutta C.
    Mueller, Thomas
    Arbeiter, Klaus
    Boehm, Michael
    Regele, Heinz
    Balzar, Egon
    Aufricht, Christoph
    PEDIATRIC TRANSPLANTATION, 2006, 10 (04) : 474 - 478
  • [4] Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy
    Falger, Jutta C.
    Mueller, Thomas
    Arbeiter, Klaus
    Boehm, Michael
    Regele, Heinz
    Balzar, Egon
    Aufricht, Christoph
    PEDIATRIC TRANSPLANTATION, 2006, 10 (05) : 565 - 569
  • [5] Methods and outcomes of calcineurin inhibitor reduction or withdrawal in patients with chronic allograft nephropathy after the first year posttransplantation
    Weir, MR
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (04) : 19S - 28S
  • [6] Is the improvement of renal function in chronic allograft nephropathy, after MMF introduction, related to cyclosporine reduction?
    Lemos, FBC
    Ianhez, LE
    Pereira, BJ
    Sabbaga, E
    David-Neto, E
    TRANSPLANTATION, 1999, 67 (07) : S86 - S86
  • [7] Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol
    Haynes, Richard
    Baigent, Colin
    Harden, Paul
    Landray, Martin
    Akyol, Murat
    Asderakis, Argiris
    Baxter, Alex
    Bhandari, Sunil
    Chowdhury, Paramit
    Clancy, Marc
    Emberson, Jonathan
    Gibbs, Paul
    Hammad, Abdul
    Herrington, Will
    Jayne, Kathy
    Jones, Gareth
    Krishnan, Nithya
    Lay, Michael
    Lewis, David
    Macdougall, Iain
    Nathan, Chidambaram
    Neuberger, James
    Newstead, Chas
    Pararajasingam, Ravi
    Puliatti, Carmelo
    Rigg, Keith
    Rowe, Peter
    Sharif, Adnan
    Sheerin, Neil
    Sinha, Sanjay
    Watson, Chris
    Friend, Peter
    TRANSPLANTATION RESEARCH, 2013, 2
  • [8] CHRONIC ALLOGRAFT NEPHROPATHY IN PROTOCOL BIOPSIES AFTER TRANSPLANTATION: ASSOCIATION WITH CALCINEURIN INHIBITOR NEPHROTOXICITY
    Pilmore, Helen
    Yehia, M.
    Merrilees, M.
    Beaumont, B.
    Dittmer, I. D.
    Collins, J.
    NEPHROLOGY, 2005, 10 : A221 - A221
  • [9] Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial
    Haynes, Richard
    Blackwell, Lisa
    Staplin, Natalie
    Herrington, William G.
    Emberson, Jonathan
    Judge, Parminder K.
    Storey, Benjamin C.
    Landray, Martin J.
    Harden, Paul N.
    Baigent, Colin
    Friend, Peter
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 (06) : 1424 - 1434
  • [10] Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy
    Weir, MR
    Ward, MT
    Blahut, SA
    Klassen, DK
    Cangro, CB
    Bartlett, ST
    Fink, JC
    KIDNEY INTERNATIONAL, 2001, 59 (04) : 1567 - 1573
12345